Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer
“Erik has proven his ability to build and lead a team that has successfully launched two rare disease treatments in North America,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “He is a strong, results-oriented leader and I’m looking forward to his continued success as he expands the scope and geographic responsibility of his role.”
“Ultragenyx has made tremendous progress in establishing a global commercial organization that has rapidly provided access to two important therapies, and I am excited to build on the launch momentum as we bring these medicines to more patients around the world,” said
Prior to joining Ultragenyx in 2017, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's website at www.ultragenyx.com.
Investors & Media
Source: Ultragenyx Pharmaceutical Inc.